Although this assessment provided insight on the lack of a significant trend with clearance within the range of AST and ALT levels in the data set, it was limited due to the exclusion of patients with significant AST and ALT elevations from the Phase 2 clinical trials.
← all excerpts
Model-Informed Paradigm in Drug Development-An End-To-End Case Study From Upadacitinib Development.
1
—
—